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One of the frequent but unrecognized side-effects of
antipsychotic medications is the subtle alterations in
subjective tolerability to these medications, including
feelings of anxiety, distress and lack of pleasure, and
which often lead to dislike and aversion to medications,
with known serious clinical consequences. Yet, those
very patients take to frequent abuse of illicit drugs.
One popular and frequently accepted explanation for
such a high association has been the self-medication
hypothesis, which proved inadequate to explain all
aspects of this phenomenon. Until recently, the neuro-
biological basis for alteration in subjective tolerability
and the negative dysphoric responses to antipsychotic
medications has not been clear, though it was generally
understood that somehow it relates to dopamine, since
all antipsychotic medications have antidopaminergic
properties. In a series of studies, including our recent
experimental dopamine depletion SPECT study, we
demonstrated for the first time the relationship between
negative subjective tolerability and dopamine-binding
ratio in the nigro-striatal area. Our findings explain to a
large part why only some patients, not all receiving anti-
psychotic medications, experience dysphoric responses,
since only those who have low baseline dopamine func-
tion are more susceptible to further dopamine-blocking
effects.
Meanwhile, emerging evidence from research in the
addiction field has implicated dopamine in the same
neural circuitry in motivational and reinforcement beha-
viour, which is central to initiation and continuation of
dependency states. It’s plausible, then, that what links
vulnerability to addictions and negative subjective toler-
ability lies in a dysregulated dopamine signaling in the
nucleus acumbens, resulting from frontal cortical and
hippocampal dysfunction. Such a proposal, though many
aspects of it have not yet been worked out clearly, and
if confirmed represents a new rethinking of the concept
of schizophrenia and its varied domains and manifesta-
tions and also has clinical implications in management.
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